SBIR/STTR Research Award

UDP -Glucuronic Acid Regeneration System

Award identifier 86ae762a02e560adacd850f95efa737ef6f5b5bc3f6ecc77fc3b09739456180cAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$966,959

Program and phase

SBIR · Phase II

Award year

2005

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
BIOCATALYTICS, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
PHS2005-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Glucuronidation is a major metabolic pathway for the inactivation and detoxification of endogenous and exogenous compounds in the human body. Glucuronides are formed by a super family of uridine diphosphoglucuronosyl transferases (UGTs) that convert a number of lipophilic xenobiotics (drugs, steroids, pollutants and pesticides) into more hydrophilic species by linking them to a polar sugar, which are then more readily eliminated from the body. Glucuronosyl derivatives of xenobiotic compounds are useful as standards in the analysis of urine or blood samples for illegal drugs, or exposure to biocides. They are also important in studies of the metabolism of new drugs, as metabolites might be more toxic or cause undesirable side effects. More recently, glucuronyl derivatives of pharmacologically active compounds have been investigated as potential prodrugs. As a result, efficient and economical methods for glucuronide production have been sought. The two main limitations for the preparative production of glucuronides needed as analytical standards are (1) the high cost of the UDP-glucuronic acid (UDPGA) co-factor and (2) the lack of availability and the relative instability of the human UGT isoforms, themselves. The former problem was resolved in the Phase I sponsored research, in which an efficient method was developed for the regeneration of UDPGA using a coupled enzyme method, thus reducing the cost of glucuronide production significantly. However, the lack of availability of the human UGTs remains to be a problem, as a result of the low yields produced in the baculovirus-infected insect cells currently used. In Phase II, we intend to solve the latter problem, by cloning and expressing 5 different UGT isozymes in E. coll., using our patented method for gene redesign and synthesis. To date, we have used this proprietary method to produce 7 human cytochromes with high activity at quantities not previously commercially available. We intend to use the knowledge gained from this to clone, express and produce human UGTs 1A1, 1A4, 1A6, 1A9 and 2B7 in the amounts necessary for the efficient synthesis of glucuronides at the preparative level.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.